IL5 and Nasal polyposis: Overall, biologic therapy with mAbs targeting IgE (omalizumab), IL-4Rα (dupilumab), or IL-5 (reslizumab, mepolizumab) led to the improvement of several clinical outcomes, including reduction size of nasal polyps, favorable impact on quality of life, nasal airflow capacity and smell.